Meina Liang

USPTO Granted Patents = 25 (Patent Applications = 8)

CIPO Patents = 2 (Patent Applications = 7)

EPO Patents = 5 (Patent Applications = 11)

Average Co-Inventor Count = 11.6

ph-index = 7

Forward Citations = 212(Granted Patents)

Location History:

Danville, CA (US) (2001 - 2012)
Fremont, CA (US) (2014)
Santa Clara, CA (US) (2016)
Gaithersburg, MD (US) (2018 - 2023)

Company Filing History:

9 out of 1,384

Schering Aktiengesellschaft

Celldex Therapeutics Limited

patents

9. 1 out of 4,179

Abbott Laboratories Corporation

patents

where one patent can have more than one assignee

Years Active: 2001-2023

Loading Chart...

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11827706 - Anti-B7-H1 antibodies for treating tumors (2023-11-28),

2. 11613580 - Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis (2023-03-28),

3. 11220541 - CCL20 as a predictor of clinical response to IL23-antagonists (2022-01-11),

4. 11016099 - Prediction of clinical response to IL23-antagonists using IL23 pathway biomarkers (2021-05-25),

5. 10829557 - Anti-B7-H1 antibodies for treating tumors (2020-11-10),

6. 10775388 - Methods of using antibodies to determine periostin levels in a sample (2020-09-15),

7. 10336823 - Anti-B7-H1 antibodies for treating tumors (2019-07-02),

8. 9862762 - Monoclonal antibodies which bind human periostin (2018-01-09),

9. 9238691 - Nucleic acids encoding antibodies to CCR2 (2016-01-19),

10. 8846873 - Antibodies directed to GPNMB and uses thereof (2014-09-30),

11. 8710191 - Antibodies to CCR2 (2014-04-29),

12. 8101178 - Antibodies directed to tumor necrosis factor and uses thereof (2012-01-24),

13. 7687606 - Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof (2010-03-30),

14. 7482434 - Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof (2009-01-27),

15. 7285269 - Antibodies directed to tumor necrosis factor (2007-10-23),

Title: The Innovative Work of Meina Liang in Cancer Research

Introduction

Meina Liang, a prominent inventor based in Danville, California, has made significant contributions to the field of cancer treatment through his innovative research. With an impressive portfolio of 25 patents, Liang continues to push the boundaries of medical science, particularly in the development of novel therapeutics.

Latest Patents

Among Liang's latest patents are groundbreaking solutions aimed at treating various tumors. One notable patent is for "Anti-B7-H1 antibodies for treating tumors," which describes methods for administering effective amounts of MEDI4736 or its antigen-binding fragments to target B7-H1-expressing tumors. Another innovative patent focuses on "Anti-PAD4 autoantibodies as clinical response biomarkers for the treatment of rheumatoid arthritis." This patent highlights the utility of anti-PAD4 autoantibodies as clinical biomarkers and provides detailed methods for their detection, including assay kits and computer-implemented diagnostic techniques.

Career Highlights

Meina Liang has worked with several prestigious organizations throughout his career, notably with Schering Aktiengesellschaft and MedImmune Limited. His experience in these companies has greatly influenced his research direction and patent development, positioning him as a key player in therapeutic advancements in oncology and autoimmune disorders.

Collaborations

Throughout his career, Liang has collaborated with esteemed colleagues such as John G. Bauman and Brad Owen Buckman. These collaborations reflect his commitment to working alongside other experts in the field to enhance the impact of his innovative discoveries.

Conclusion

With 25 patents to his name and a strong background in cancer treatment research, Meina Liang exemplifies the spirit of innovation in the field of medicine. His work continues to pave the way for new therapeutic options, ultimately improving patient outcomes and advancing scientific knowledge.

This text is generated by artificial intelligence and may not be accurate.